Quick Answer: Cosmetics and quasi-drugs are different legal categories in Japan. Ordinary cosmetics follow cosmetic requirements, while quasi-drugs generally require product marketing approval. Classification depends on the actual intended use, formula and claims. An English description such as “cosmeceutical” does not establish a Japanese category. Decide the route with the Japanese responsible operator before finalising the formula, packaging or launch commitments.
Begin with the statutory product purpose
The Japanese Pharmaceuticals and Medical Devices Act defines cosmetics through purposes such as cleansing, beautifying, changing appearance and keeping skin or hair healthy, with mild action on the body. Its definition excludes quasi-drugs and products also intended for specified medicinal purposes. Quasi-drugs have their own statutory scope, including designated categories. The complete product presentation matters when applying those definitions.
For a brand, the useful starting document is a product brief that records intended users, application site, frequency, directions, format and every proposed benefit. Attach the quantitative formula and identify ingredients being presented for a particular function. Translate the intended meaning of the claims, rather than assuming that a literal Japanese translation will remain appropriate.
A familiar bottle shape gives little guidance. Two similar looking lotions can follow different routes because their authorised purposes and formulation differ. Equally, a more expensive ingredient or a laboratory-style package does not make an ordinary cosmetic a quasi-drug. Ask the Japanese reviewer to explain the proposed classification in writing, including any unresolved point that requires authority consultation.
| Question | Ordinary cosmetics | Quasi-drugs |
|---|---|---|
| Classification | Cosmetic purpose within the statutory definition | Within the applicable quasi-drug scope |
| Product approval | Generally unnecessary for compliant ordinary cosmetics | Generally required for the individual product |
| Claims review | Within permitted cosmetic expression and supported presentation | Consistent with the approved efficacy and use |
| Formula review | Standards for Cosmetics and relevant current requirements | Applicable approval route, composition and specifications |
Separate product approval from business responsibilities
The PMDA FAQ on cosmetics and quasi-drugs explains that cosmetic products do not need a marketing approval application but must comply with the Standards for Cosmetics. It also explains that products with active ingredients are generally classified as quasi-drugs and require approval. Read that summary alongside the statutory scope and the exact product circumstances; it is not a rule that every ingredient described as an “active” in overseas marketing automatically determines classification.
A product approval exemption does not make a cosmetic an unregulated product. The Japanese supply arrangement still needs the appropriate business permissions, product procedures and continuing quality and safety responsibilities. Identify the Japanese manufacturing and marketing operator, confirm the actual licensed activities and agree who can authorise release. Do this before treating an overseas manufacturer’s certificate as enough to enter the market.
For quasi-drugs, PMDA’s quasi-drug review page describes the approval system and links to the application and consultation resources. Determine the relevant category, applicable approval standards and competent authority for the actual case. Do not promise that every quasi-drug application is reviewed through an identical process or that a familiar ingredient guarantees an easy approval. The brand’s commercial deadline should follow the verified route.
Keep business permissions, product approval, technical evidence and individual batch release as distinct records in the project plan. Give each record an owner and a dependency. A sample that performs well in a consumer study cannot replace the relevant approval, and an approval number cannot resolve a later manufacturing deviation.
Review claims before the formula and artwork are locked
Collect proposed claims from every customer touchpoint: the carton, bottle, website, marketplace listing, training presentation and social media brief. Build a claim register with the original wording, intended Japanese meaning, supporting evidence and reviewer decision. Include product names and images where they imply a benefit. Review the overall impression as well as individual sentences.
Ordinary cosmetic claims need to remain within the applicable cosmetic scope. Quasi-drug communication must stay consistent with the approved efficacy, directions and conditions. A result observed in a study does not independently expand a lawful claim. Avoid presenting an ordinary cosmetic as treating a disease or borrowing a quasi-drug claim because a competing product uses similar ingredients.
Consider a moisturising lotion brief that later acquires an acne prevention message. The project team should reopen the classification review before sending that revision to design. It should not assume that adding a sentence is merely a copy change. Conversely, removing a promotional phrase does not by itself settle the route when the intended use and composition still raise questions.
For cross-market portfolios, our ASEAN notification overview illustrates a different regulatory arrangement. An ASEAN notification, a foreign drug listing or a supplier’s export history does not establish Japan’s classification. Maintain a separate country decision for the same commercial product, and use distinct artwork masters when the lawful presentation differs.
Make classification questions reviewable
Intended use: Does the complete use fit the proposed category?. Agreed product brief and rationale.
Composition: Are ingredient functions and quantities suitable for the route?. Controlled quantitative formula.
Benefit wording: Is the proposed message within the lawful scope?. Reviewed Japanese claim register.
Product evidence: Does support apply to this formula and use?. Study index with applicability notes.
Handle ingredient highlights with current Japanese guidance
MHLW issued updated guidance on highlighting specific cosmetic ingredients on 10 March 2025. The notice addresses the risk that ingredient emphasis makes consumers think the ingredient is an approved active. Where a permitted highlight is used, its cosmetic or formulation purpose must be stated and objectively substantiated. The guidance also addresses foreign-language expressions, design and readability.
This deserves a separate artwork check when the export master prominently says “active complex” or gives an ingredient a large visual treatment. Record the proposed ingredient function, the evidence for that function and the way the explanation will appear next to the highlight. Have the Japanese reviewer assess the final design, including footnotes and mobile presentation. A function buried in unreadable text is not a useful review outcome.
The notice also addresses highlighting non-approved-active ingredients in quasi-drugs by reference to cosmetic-style treatment. Do not describe every ingredient in an approved quasi-drug as an approved active ingredient. Keep the product’s approved active role distinct from supporting formulation ingredients when preparing technical and marketing documents.
This guidance does not provide a universal classification shortcut or an ingredient concentration permission. Consult the MHLW cosmetics and quasi-drugs resource page for current standards and notifications. An older English summary can orient a project team, but should not be used to declare that a concentration, preservative or UV filter is currently permitted. This article does not prescribe ingredient limits.
Give the manufacturer a precise evidence request
Start the manufacturer handoff with the agreed category and exact formula revision. Request ingredient identities, quantitative composition including constituents of blends, relevant specifications, manufacturing site details and available finished-product test reports. Identify information still under development. A generic specification sheet should not silently stand in for a report on the actual product.
Work with the OEM/ODM cosmetics manufacturer to map existing records to the Japanese reviewer’s request. Use a secure disclosure arrangement for confidential composition while ensuring the responsible reviewer can access what is needed. Resolve unclear trade names, differing raw-material identifiers and unrecorded substitutions before the reviewer reaches a conclusion.
For a proposed quasi-drug, the evidence plan must follow the actual application category and the authority’s requirements. Determine what composition, specifications, manufacturing, safety and efficacy material is required for that case. Do not assume that a cosmetic dossier can simply be relabelled, or that an ingredient supplier’s published study automatically supports the finished product’s approval.
For an ordinary cosmetic, build a proportionate safety and quality record for the formula, packaging and foreseeable use. Stability, microbiological control and compatibility information may all be relevant, depending on the product. Agree the testing rationale with the responsible technical team. These preparation steps support review; they do not amount to a claim that MOOYAM holds Japanese quasi-drug approval.
Allocate the work without confusing the parties
Classification: Accurate formula and intended function information. Confirm route and obtain local regulatory assessment.
Evidence: Controlled technical files and study explanations. Identify requirements and assess remaining gaps.
Artwork: Pack specification and production proof. Approve Japanese claims and required particulars.
Market maintenance: Batch investigation and advance change notice. Local reporting, release and regulatory decisions.
Use release gates that match the chosen route
Create a short decision log before ordering printed packaging. Gate one is the agreed product identity and route. Gate two is the reviewed formula and evidence plan. Gate three is the completed applicable product procedure, with any approval verified for the quasi-drug case. Gate four is the approved physical pack and release arrangement. Leave a gate open when its evidence is incomplete.
The final artwork review should compare the product name, formula identity, directions, warnings and responsible business details against the controlled master. For a quasi-drug, also reconcile the communication with the actual approved particulars. Inspect the printed proof at realistic size and retain the approved version. Review the corresponding online listing with the same claim register.
Plan regulatory time and cost after the route has been confirmed. A new benefit, a different active system or an evidence gap may change the work substantially. Do not publish a universal approval duration or fee based on another product’s experience. Ask the responsible operator to verify the current procedure and identify dependencies before a launch date is announced.
Classification and release sequence
1. Product brief: Agree intended use and category. Retain written rationale with unresolved questions closed.
2. Technical review: Confirm formula and evidence suitability. Retain reviewed master and gap assessment.
3. Regulatory procedure: Complete the applicable route. Retain verified filing or approval record as relevant.
4. Release: Approve pack and supply arrangement. Retain signed artwork and documented release decision.
Keep the classification decision current after launch
Introduce change control for the formula, raw-material source, manufacturing site, intended users, directions, packaging and claims. Send the proposed change to the Japanese responsible team before implementation. The significance of a change depends on the route and the actual approved or notified particulars; it should not be decided solely by whether the consumer can see it.
Connect complaints and investigation records to batch numbers and the product revision. Agree how the manufacturer will provide information and how the Japanese operator will determine the local response. Maintain contact details and records when a distributor or brand team changes. A well organised handover should allow a new reviewer to understand why the product follows its route.
To organise a manufacturing document handoff, contact the project team with the intended use, proposed claims, formula status and Japanese operator arrangements. Product-specific Japanese review remains necessary. Commercial supply discussions should not be interpreted as a promise of classification, regulatory approval or permission to use a particular benefit statement.
Frequently asked questions
Does “cosmeceutical” mean quasi-drug in Japan?
No. An English marketing term does not determine the legal category. Review the actual intended use, formula, claims and relevant Japanese statutory scope.
Do ordinary cosmetics require product marketing approval?
PMDA explains that cosmetic marketing approval applications are unnecessary, provided the product complies with the Standards for Cosmetics. Appropriate business permissions, product procedures and continuing responsibilities still need to be addressed.
Does an ingredient called an active automatically make a quasi-drug?
Overseas marketing terminology is insufficient. Establish the ingredient’s actual role and evaluate the complete product under Japanese requirements. Do not infer an approval from an ingredient name.
Can a quasi-drug make any medical claim?
No. Communication must remain consistent with the product’s approved efficacy and use, and applicable advertising requirements. A quasi-drug approval does not authorise unrestricted disease treatment claims.
What should a brand settle before commissioning packaging?
Confirm the category, formula revision, Japanese responsible operator, evidence gaps and reviewed claims. For a quasi-drug, coordinate the artwork with the actual approval particulars before final print release.
Last reviewed: 25 October 2026. General planning information only, not product-specific legal, regulatory or safety advice. Confirm current Japanese requirements and the appropriate route with a qualified Japanese regulatory professional before manufacture, import, advertising or sale.